Published in J Virol on October 18, 2006
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med (2009) 2.24
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med (2015) 1.67
Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe (2014) 1.57
Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun (2009) 1.56
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine (2009) 1.56
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine (2009) 1.51
Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine (2010) 1.43
Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS One (2011) 1.36
Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 1.30
Protective B cell responses to flu--no fluke! J Immunol (2011) 1.28
Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods (2008) 1.28
Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis (2008) 1.18
Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol (2011) 1.17
Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine (2008) 1.16
Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis (2010) 1.12
Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One (2008) 1.11
Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods (2010) 1.09
An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses (2012) 1.03
Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis (2012) 1.03
Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J Immunol (2011) 0.99
An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine (2011) 0.99
Characterization of rotavirus specific B cells and their relation with serological memory. Virology (2008) 0.98
Re-engaging cross-reactive memory B cells: the influenza puzzle. Front Immunol (2012) 0.97
Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis (2015) 0.96
Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. J Infect Dis (2014) 0.93
Immunity to viruses: learning from successful human vaccines. Immunol Rev (2013) 0.92
Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J Infect Dis (2014) 0.91
H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines. PLoS One (2009) 0.91
Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine (2015) 0.90
Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol (2011) 0.90
Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol J (2011) 0.90
Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell (2010) 0.89
Human rotavirus-specific IgM Memory B cells have differential cloning efficiencies and switch capacities and play a role in antiviral immunity in vivo. J Virol (2012) 0.87
Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination. J Infect Dis (2014) 0.86
Rotavirus differentially infects and polyclonally stimulates human B cells depending on their differentiation state and tissue of origin. J Virol (2010) 0.86
Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza. Influenza Other Respir Viruses (2008) 0.86
An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin. BMC Biotechnol (2015) 0.85
Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice. J Virol (2011) 0.84
Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection. J Infect (2014) 0.84
The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoS One (2015) 0.84
The human side of influenza. J Leukoc Biol (2012) 0.83
Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay. Viral Immunol (2014) 0.83
Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis (2014) 0.82
Innate immune sensing and response to influenza. Curr Top Microbiol Immunol (2015) 0.82
Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS One (2015) 0.81
Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers in South Apulia, Italy: a pilot study. J Clin Med Res (2011) 0.80
B Cells and Functional Antibody Responses to Combat Influenza. Front Immunol (2015) 0.79
Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain. Genome Med (2015) 0.79
Ex vivo analysis of human memory B lymphocytes specific for A and B influenza hemagglutinin by polychromatic flow-cytometry. PLoS One (2013) 0.78
Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight (2016) 0.78
Evaluation of the innate immune responses to influenza and live-attenuated influenza vaccine infection in primary differentiated human nasal epithelial cells. Vaccine (2017) 0.77
Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Hum Vaccin Immunother (2015) 0.76
Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Hum Vaccin Immunother (2015) 0.75
Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight (2017) 0.75
Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) in Adults. Clin Vaccine Immunol (2016) 0.75
The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. Front Immunol (2017) 0.75
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine (2005) 5.55
Emerging infections: pandemic influenza. Epidemiol Rev (1996) 4.85
Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods (2004) 4.57
Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc Natl Acad Sci U S A (2002) 4.02
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA (1999) 3.53
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Maintenance of serum antibody levels. Annu Rev Immunol (2005) 3.20
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 2.67
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine (2002) 2.47
An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine (1994) 2.09
Specific in vitro antibody response to influenza virus by human blood lymphocytes. Nature (1979) 2.08
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine (2005) 2.04
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Immunological memory in humans. Semin Immunol (2004) 1.90
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
A mixture model with detection limits for regression analyses of antibody response to vaccine. Biometrics (1995) 1.87
An overview of serum antibody responses to influenza virus antigens. Dev Biol (Basel) (2003) 1.84
Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine (1989) 1.52
Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis (2002) 1.48
Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis (1998) 1.24
Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J (2004) 1.21
In vitro production of anti-influenza virus antibody after intranasal inoculation with cold-adapted influenza virus. J Immunol (1981) 1.21
Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J (2000) 1.17
Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J (2004) 1.15
Expression of alpha4beta7 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sites. J Leukoc Biol (2000) 1.07
Differential expression of chemokine receptors on human IgA+ and IgG+ B cells. Clin Exp Immunol (2005) 1.03
Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine (1999) 1.02
Influenza. The role of burden-of-illness research. Pharmacoeconomics (1999) 0.90
Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology (2006) 0.87
Role of influenza vaccine for healthy children in the US. Paediatr Drugs (2004) 0.85
Human peripheral blood mononuclear cells produce IgA anti-influenza virus antibody in a secondary in vitro antibody response. J Immunol (1985) 0.84
Influenza-associated deaths among children. N Engl J Med (2006) 0.81
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med (2013) 3.41
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med (2002) 2.73
Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med (2013) 2.71
Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 2.67
Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37
Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol (2002) 2.28
Genetic measurement of memory B-cell recall using antibody repertoire sequencing. Proc Natl Acad Sci U S A (2013) 2.25
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology (2006) 2.03
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis (2008) 2.02
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2013) 2.00
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A (2002) 1.92
Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99. Virology (2005) 1.91
Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A (2005) 1.89
Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med (2004) 1.85
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis (2012) 1.80
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis (2001) 1.77
A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol (2007) 1.76
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol (2013) 1.75
Immunity and correlates of protection for rotavirus vaccines. Vaccine (2006) 1.73
Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. Science (2009) 1.66
The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J Exp Med (2002) 1.59
Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology (2003) 1.57
T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest (2004) 1.56
Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol (2006) 1.54
Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol (2002) 1.53
The Apnea Positive Pressure Long-term Efficacy Study (APPLES): rationale, design, methods, and procedures. J Clin Sleep Med (2006) 1.52
Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol (2004) 1.52
Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J Immunol (2013) 1.51
Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation (2006) 1.46
Gene expression pattern in Caco-2 cells following rotavirus infection. J Virol (2002) 1.46
Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol (2006) 1.46
Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol (2013) 1.45
Military-related sexual trauma among Veterans Health Administration patients returning from Afghanistan and Iraq. Am J Public Health (2010) 1.39
Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol (2003) 1.39
The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol (2009) 1.38
The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology (2002) 1.37
Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol (2007) 1.37
Simple counts of ADL dependencies do not adequately reflect older adults' preferences toward states of functional impairment. J Clin Epidemiol (2008) 1.37
Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis (2010) 1.36
Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Invest (2002) 1.34
Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol (2003) 1.33
The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J Virol (2011) 1.30
Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol (2002) 1.29
Varicella in the fetus and newborn. Semin Fetal Neonatal Med (2008) 1.29
IRF3 inhibition by rotavirus NSP1 is host cell and virus strain dependent but independent of NSP1 proteasomal degradation. J Virol (2009) 1.29
Keratin 20 helps maintain intermediate filament organization in intestinal epithelia. Mol Biol Cell (2003) 1.29
Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J (2007) 1.28
Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J Immunol Methods (2003) 1.27
Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol (2003) 1.25
Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol (2008) 1.23
Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires. J Immunol (2003) 1.22
Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J (2004) 1.21
Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis (2004) 1.20
Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine (2003) 1.20
Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. J Infect Dis (2003) 1.19
A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis (2006) 1.19
T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol (2005) 1.19
Frequencies of virus-specific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol (2002) 1.17
Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J Virol (2004) 1.17
Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A (2011) 1.16